AusperBio has entered the HBV siRNA race, but can AHB-171 move beyond antigen suppression?
AusperBio has dosed the first patient with AHB-171, testing a liver-targeted siRNA candidate and a broader combination strategy for hepatitis B.
Pharma & Biotech
Pharma & Biotech
Why Brii Bio’s BRII-179 sequencing data could reshape hepatitis B combination treatment
See how Brii Bio’s Phase 2b hepatitis B data support BRII-179 immune priming while durability and Phase 3 risks remain.
Pharma & Biotech
Russell 2000 inclusion puts Precision BioSciences before more investors at a pivotal clinical stage
See how Russell 2000 inclusion expands Precision BioSciences’ investor reach while PBGENE-HBV and PBGENE-DMD face critical clinical tests.
Pharma & Biotech
TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy
Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.
Pharma & Biotech
Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin
China has hepatitis B scale. GSK has bepirovirsen. SBP Group may decide whether science can become real-world access.
Pharma & Biotech
Can Brii Bio’s HBV rebound data move functional cure closer to clinical reality?
HBV cure hopes depend on durability, not just antigen loss. Brii Bio’s APASL data shifts attention to post-treatment control.
Pharma & Biotech
AusperBio’s AHB‑137 enters final testing phase in HBeAg-negative chronic hepatitis B patients
AusperBio Therapeutics has completed patient enrollment in its Phase III AUSHINE trial evaluating AHB‑137 for the treatment of HBeAg-negative chronic hepatitis B. The randomized, double-blind, multicenter study, launched in China under regulatory clearance from the Center for Drug Evaluation, surpassed its initial enrollment goal with over 570 patients enrolled within five months. AHB‑137 is being
Pharma & Biotech
Could AHB-137 set a new benchmark for HBV cure rates? Insights from AusperBio’s 24-week monotherapy trial
AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s